If liver cancer — or a suspicious nodule on a scan — has entered your life, this page was written to give you the clearest map through it: how it is found early, how it is staged, and why early liver cancer is genuinely curable.
Medically reviewed by Dr. Srinivas Bojanapu · September 2026
10,000+
Patients Treated
15+ Years
Surgical Experience
24/7
Emergency Care
Liver cancer in 30 seconds
- What it is: hepatocellular carcinoma (HCC) — the commonest primary liver cancer (75–85% of cases), arising almost always in already-diseased livers: hepatitis B/C, fatty liver, alcohol, cirrhosis.
- The paradox: it causes no symptoms early — but it is one of the few cancers with a reliable early-detection test.
- The life-saving habit: 6-monthly ultrasound + AFP in at-risk livers — the 20-minute half-yearly check that catches cancer while it is still curable.
- If a nodule is found: a triple-phase CT/MRI characterises it; treatment follows stage — and early cancer is curable.
- By stage: resection or ablation cures early disease; TACE controls intermediate; immunotherapy extends advanced; transplant cures cancer and cirrhosis together.
Understanding liver cancer (HCC)
Hepatocellular carcinoma is the most common cancer that starts in the liver. Its defining feature: about 80% of HCC arises in cirrhotic livers — which is bad news (the diseased liver is vulnerable) and good news (the at-risk population is known, identifiable, and surveillable). India's rising HCC rates track its hepatitis B, hepatitis C and fatty-liver burden.
Why surveillance is the real cure
The liver is famously silent: early HCC causes no symptoms. By the time pain, weight loss or jaundice appear, the disease is usually advanced. That is why every patient with cirrhosis, chronic hepatitis B (even without cirrhosis), or advanced fatty-liver fibrosis keeps a calendar: ultrasound + AFP every 6 months.
- Ultrasound — the primary tool; 60–80% sensitive for HCC
- Serum AFP — tumour marker, raised in 60–70% of HCC (supportive, not specific)
- If a nodule appears — triple-phase CT or MRI characterises it in minutes
- The arithmetic that saves lives: early HCC (single nodule under 3 cm, good liver function) carries a 5-year survival of 60–70% with resection or transplant; late HCC with vessel invasion measures survival in months. Annual (not 6-monthly) surveillance misses 30–40% of cancers that grow unresectable between scans.
Risk factors — who carries the calendar
High-risk conditions
- Liver cirrhosis of any cause — 80% of HCC arises here
- Chronic hepatitis B — even without cirrhosis
- Chronic hepatitis C with cirrhosis
- NASH cirrhosis — rapidly rising
- Alcoholic cirrhosis
- Aflatoxin exposure (contaminated grains)
Other risk factors
- Haemochromatosis (iron overload)
- Alpha-1 antitrypsin deficiency
- Diabetes and obesity
- Family history of liver cancer
- Male sex (3:1); age over 50
When to see a doctor — promptly
- Any new right-upper-abdominal pain or lump in a known cirrhotic
- Unexplained weight loss with liver disease
- New jaundice or abdominal swelling
- A nodule seen on any ultrasound — same-week characterisation, never watch-and-wait
Emergency
- Vomiting blood or black stools (variceal bleed)
- Sudden severe abdominal pain
- Confusion or drowsiness
- Call 87478 74666 — 24/7 emergency service
How is liver cancer diagnosed? A step-by-step journey
- Risk identification. Cirrhosis, chronic hepatitis B, advanced fibrosis — the calendar starts here.
- Surveillance. 6-monthly ultrasound + AFP — the test that finds HCC before symptoms exist.
- Characterisation. A nodule goes to triple-phase CT or MRI: in cirrhotic livers, the classic enhancement-washout pattern is diagnostic by international criteria — no biopsy needed (biopsy risks seeding the tumour).
- Liver assessment. MELD score, Child-Pugh class and liver stiffness — because the plan must fit the patient and the liver.
- Staging — BCLC. The system that maps every patient to the right treatment (below).
- Multidisciplinary plan. Surgeon, oncology, radiology and transplant input agree one pathway — honestly, including when referral elsewhere serves you better.
Staging — the BCLC system, plainly
| BCLC stage | What it means | Typical treatment |
|---|---|---|
| 0 — Very early | Single nodule <2 cm, good liver function | Resection or ablation (RFA/MWA) — potentially curative |
| A — Early | Single tumour, or up to 3 nodules ≤3 cm | Resection, transplant, or ablation — potentially curative |
| B — Intermediate | Multiple nodules, no vessel invasion | TACE — controlling tumours for years |
| C — Advanced | Portal vein invasion or spread | Systemic therapy (immunotherapy combinations) |
| D — Terminal | Very poor liver function | Best supportive care |
Staging describes scan findings; your final plan is individualised after multidisciplinary review — this table is general information, not a plan for you.
Treatment — decided by stage, not by default
Curative — resection
What: surgical removal of the tumour-bearing liver segment (laparoscopic or open). Why/when: best for single tumours in a liver healthy enough to survive the loss — non-cirrhotic livers, or selected cirrhotics (Child A, adequate remnant volume). Outcomes: 5-year survival 50–70%. Limitations: the cirrhotic liver's reserve decides — we operate on the patient and the liver, not just the tumour.
Curative — liver transplantation
What: replacing the liver — removing the cancer and the diseased liver that produced it. When: single HCC ≤5 cm, or up to 3 nodules all ≤3 cm, with cirrhosis (Milan criteria); larger tumours may be downstaged with TACE first. Outcomes: 5-year survival 65–75%. See our liver transplant page.
Curative — ablation (RFA/MWA)
What: heat delivered through a needle directly into the tumour, destroying it — percutaneous, laparoscopic or open. When: small HCC (<3 cm) in patients unfit for surgery; outcomes comparable to surgery for very small tumours. Limitations: tumour size and location decide suitability.
Control — TACE and SIRT
TACE: chemotherapy (doxorubicin) delivered into the tumour's artery, followed by particles cutting off its blood supply — for intermediate-stage disease; significantly prolongs survival and can downstage to cure. SIRT (Y-90): radioactive microspheres delivered into the hepatic artery — an alternative for some, effective even with portal vein involvement.
Advanced disease — systemic therapy
What: tablets and immunotherapy combinations — sorafenib or lenvatinib first-line; atezolizumab + bevacizumab (superior outcomes in recent trials); second-line regorafenib, cabozantinib, ramucirumab. Why: meaningful survival gains in advanced HCC. Limitations: these extend life; they do not cure — honesty is part of the plan.
Supportive and palliative care
What: pain, nutrition, jaundice and symptom care running alongside everything above — see Pain & Palliative Care. Why: comfort is a treatment, at every stage.
What happens after a nodule is found — the usual pathway
- Nodule on surveillance ultrasound — the system working as designed
- Triple-phase CT/MRI — characterised without biopsy in most cases
- Liver assessed — MELD, Child-Pugh, stiffness, remnant volume
- BCLC stage assigned — multidisciplinary review
- Treatment delivered — resection / ablation / TACE / systemic / transplant
- Aftercare — surveillance continues; recurrence is caught early and re-treated
What is the outlook?
Honest in both directions. Found in surveillance: early HCC is genuinely curable — 50–75% five-year survival across resection, ablation and transplant. Found after symptoms: usually advanced, where therapy extends rather than cures — median survival measured in months to years depending on stage and response. That gap is the entire argument for the 6-monthly calendar: in liver cancer, the surveillance habit you keep decides the treatment you get.
Nutrition and daily life
Protect the liver you have
Zero alcohol; cautious with every medicine — paracetamol doses as advised, no NSAIDs without your team; no unverified herbal 'liver tonics'.
Eat for the liver
Small, frequent, protein-positive meals; salt restriction if ascites appears; our dieticians tailor plans to Child-Pugh stage.
Keep the calendar sacred
6-monthly ultrasound + AFP before and after treatment — recurrence caught early is re-treatable.
Living with the worry
Surveillance converts fear into data. Bring a family member to reviews; ask for your numbers; a second opinion is reasonable at any crossroads.
Questions to ask your doctor
- What exactly did the CT/MRI show — how many nodules, what size?
- What is my BCLC stage — and what is my Child-Pugh/MELD?
- Am I candidate for resection — is my liver reserve enough?
- Do I qualify for ablation — or for transplant under Milan criteria?
- Does TACE fit my stage — and could it downstage me to cure?
- What systemic options exist — and what is their honest goal?
- What is my surveillance schedule after treatment?
If you would like more confidence about your diagnosis or treatment plan, seeking a second opinion is reasonable.
Frequently Asked Questions
Can liver cancer be cured?
Yes — when found early. Early-stage liver cancer (BCLC 0/A) can be cured with surgical resection, transplantation, or ablation, with 5-year survival rates of 50–75%. The key is early detection through regular surveillance in at-risk patients (cirrhotics, HBV carriers). Advanced HCC cannot be cured, but survival can be extended with systemic therapy.
Who should get 6-monthly liver cancer screening?
Everyone with cirrhosis (any cause), chronic hepatitis B (even without cirrhosis), and advanced fibrosis from fatty liver or hepatitis C. Screening = ultrasound + AFP. It takes minutes, costs little, and saves lives.
How often — really — is surveillance needed?
Every 6 months with liver ultrasound + AFP. This is non-negotiable: annual surveillance misses 30–40% of HCCs that grow to unresectable size between annual scans. 6-monthly surveillance is the international standard.
What are the symptoms of liver cancer?
Early HCC typically causes no symptoms — it is detected on surveillance. Symptomatic HCC (right upper-abdominal pain, weight loss, jaundice, ascites) is usually advanced. This is exactly why surveillance in cirrhotic patients and HBV carriers matters so much.
Is biopsy always needed to diagnose liver cancer?
No. In cirrhotic livers, typical arterial enhancement followed by washout on triple-phase CT/MRI is diagnostic by international criteria — biopsy is avoided (risk of tumour seeding). Biopsy is reserved for atypical lesions.
What is TACE and when is it used?
Transarterial chemoembolisation delivers chemotherapy directly into the tumour's artery and blocks its blood supply — used for intermediate-stage multifocal tumours when surgery is not suitable. It can control disease for extended periods, and is also used to downstage tumours to curative intent.
My liver is cirrhotic — can it handle cancer surgery?
This is the central question of HCC care: we operate on the patient and the liver, not just the tumour. MELD score, liver stiffness and remnant-volume calculations decide resectability. When the liver is too sick, ablation, TACE or transplant take precedence — the plan follows liver reserve.
How Dhaara Speciality Hospital can help
And if you need us, here is what stands ready for you under one roof in Yelahanka, Bangalore:
- Full hepatobiliary assessment — triple-phase CT/MRI, AFP, liver-reserve staging
- Surgical resection — laparoscopic and open liver resections
- Ablation guidance and TACE coordination — the right modality for the right tumour
- Transplant evaluation — Milan-criteria assessment and referral, see liver transplant
- Surveillance programmes — 6-monthly ultrasound + AFP, on protocol
- Supportive care — see Pain & Palliative Care; 24/7 emergency care
Dr. Srinivas Bojanapu
MBBS, MS, FACRSI, DrNB, PDF — Surgical Gastroenterologist & HPB Surgeon with 16+ years of experience and 5,000+ procedures.
Medically reviewed by Dr. Srinivas Bojanapu — MBBS, MS, FACRSI, DrNB, PDF · Surgical Gastroenterologist & HPB Surgeon · Last updated: September 2026.
This page provides general information and is not a substitute for personal medical advice, diagnosis or treatment. Treatment decisions are always individualised after clinical assessment.
Sources & standards:
- Institutional figures on this page (patients treated, survival context) are based on Dhaara Hospital records and published hepatology literature.
- HCC management follows internationally accepted guidance (AASLD/EASL, BCLC staging).
Book Your Consultation
In liver cancer, the calendar is the cure. Start or resume your 6-monthly surveillance — or get a nodule characterised — at Dhaara Speciality Hospital, Yelahanka.
Words From Our Happy Clients
Glowing testimonials from satisfied clients share their positive experiences.
Dhaara Speciality Hospital is a trusted healthcare institution equipped with state-of-the-art facilities and a team of skilled surgeons, including specialists in laparoscopic procedures. Choosing Dhaara for your laparoscopic gallbladder surgery comes with several advantages.
More Reviews
Vinay T
India
Surprised at the excellent facilities
I visited Dhaara Hospital and consulted with Dr. Prathima, a fantastic gynecologist. She's professional, friendly, and listens to my concerns. Her treatment worked well for me, and she always suggests the best.
Suchetha
India
Surprised at the excellent facilities
Dr Sreenivas is brilliant. The way, he listens to the patients issue giving so much time inspite of his busy schedule. I am very happy to have met him for my mom's surgery. Best Gastro surgeon👏👏.
.webp)
.webp)
